Pts with PD-L1+ metastatic NSCLC who had disease progression following one or more prior lines of anti-PD-1/L1-containing treatment; arm A, GEN1046 100 mg Q3W x 2 cycles then 500 mg Q6W, N=16; arm B, GEN1046 100 mg + pemb 200 mg Q3W, N=22; arm C, GEN1046 100 mg + pemb 400 mg Q6W, N=24;. This evidence concerns the gene CD274 and non-small cell lung carcinoma.